Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older at the time of signing the consent form
• People with a good general health and activity level (able to carry out normal daily activities with little or no limitation, based on a standard medical scoring scale)
• People diagnosed with HER2-positive cancer of the esophagus (food pipe), the gastroesophageal junction (where the food pipe meets the stomach), or the stomach, confirmed by a biopsy or surgical sample using specific laboratory tests
• People whose cancer can be fully removed by surgery
• People whose blood counts, kidney, liver, and clotting levels meet the specific health thresholds required by the trial (confirm with trial site)
• Male participants who agree to use contraception during treatment and for at least 230 days after the last dose, and who agree not to donate sperm during this period
• Female participants who are not pregnant or breastfeeding, and who either are not of childbearing potential, or who agree to use contraception during treatment and for at least 170 days after the last dose

Who may not be able to join:

• People whose cancer has spread to other parts of the body or has come back after previous treatment
• People who have already received any treatment for esophageal or stomach cancer
• People who have previously been treated with certain types of immunotherapy drugs that target PD-1, PD-L1, or CTLA-4 pathways
• People who have previously been treated with a HER2-targeted therapy
• People whose heart pumping function is below 50% on a recent heart scan (though those with a result between 45–49% may be considered in certain circumstances, at the doctor's discretion)
• People who are currently taking part in another clinical trial or who have received an experimental treatment or used an experimental device within the past 4 weeks
• People who have been diagnosed with an immune system deficiency, or who have been taking steroid or other immune-suppressing medications in the 7 days before starting the trial (some short-term or low-dose exceptions may apply — confirm with trial site)
• People with a known history of active tuberculosis (TB)
• People with a known allergy or sensitivity to pembrolizumab or any of its ingredients
• People who have been diagnosed with or treated for another cancer in the past 3 years, not including certain common skin cancers
• People with cancer that has spread to the brain or the lining around the brain or spinal cord
• People with a known history of, or currently active, non-infectious lung inflammation
• People currently dealing with an active infection that requires treatment through the bloodstream (such as IV antibiotics)
• People with a medical condition, ongoing treatment, or abnormal test result that the trial doctor believes could interfere with the trial or would not be in the person's best interest
• People with known psychiatric conditions or substance use issues that would make it difficult to follow the trial requirements
• People who are pregnant, breastfeeding, or planning to become pregnant or father a child during the trial period and up to 120 days after the last dose
• Women of childbearing potential who have a positive pregnancy test within 72 hours before being assigned to the trial
• People who have received a transplanted organ or tissue from another person
• People with an active or recent history (within the past 3 years) of autoimmune or inflammatory conditions such as inflammatory bowel disease, lupus, rheumatoid arthritis, or similar conditions (some exceptions apply, such as stable thyroid conditions or vitiligo — confirm with trial site)
• People with a known history of HIV
• People with currently active Hepatitis B or Hepatitis C infection
• People who have received a live vaccine within 30 days before starting the trial (some inactivated flu vaccines may be permitted — confirm with trial site)
• People who are unwilling or unable to give informed consent or follow the trial requirements for its full duration

Important: Always verify eligibility with the trial site directly before applying.